Integrated Filing — IndAS



General information about company

Scrip Code 540596
NSE Symbol ERIS
MSEI Symbol NOTLISTED
ISIN INE406M01024
Name of company Eris Lifesciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 26-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 19-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 26-10-2026   11:00:00
End date and time of board meeting 26-10-2026   13:40:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? Yes
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? Yes
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 07-08-2023
Indicate Company website link for updated RPT policy of the Company https://www.eris.co.in/investor-relations/disclosures-regulation-46
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicabe



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 48,224.00 92,624.00
Other income 1,924.00 4,562.00
Total income 50,148.00 97,186.00
2 Expenses
(a) Cost of materials consumed 1,874.00 3,873.00
(b) Purchases of stock-in-trade 14,162.00 26,972.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,228.00) 44.00
(d) Employee benefit expense 8,201.00 17,285.00
(e) Finance costs 4,206.00 8,422.00
(f) Depreciation, depletion and amortisation expense 4,088.00 8,086.00
(f) Other Expenses
1 Other Expenses 6,904.00 14,148.00
Total other expenses 6,904.00 14,148.00
Total expenses 38,207.00 78,830.00
3 Total profit before exceptional items and tax 11,941.00 18,356.00
4 Exceptional items (3,590.00) (3,590.00)
5 Total profit before tax 8,351.00 14,766.00
6 Tax expense
7 Current tax 1,385.00 2,408.00
8 Deferred tax (5,949.00) (5,388.00)
9 Total tax expenses (4,564.00) (2,980.00)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 12,915.00 17,746.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 12,915.00 17,746.00
17 Other comprehensive income net of taxes (57.00) (45.00)
18 Total Comprehensive Income for the period 12,858.00 17,701.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,387.00 1,387.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 9.32 12.81
Diluted earnings (loss) per share from continuing operations 9.31 12.8
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 9.32 12.81
Diluted earnings (loss) per share from continuing and discontinued operations 9.31 12.8
24 Debt equity ratio 0.600 0.600
25 Debt service coverage ratio 2.4900 2.0500
26 Interest service coverage ratio 3.8400 3.1800
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 12,572.00
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 4,857.00
Other intangible assets 2,11,238.00
Intangible assets under development 605.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 1,41,406.00
Trade receivables, non-current 0.00
Loans, non-current 55,155.00
Other non-current financial assets
1 Other Financial Asset 504.00
Total of other non-current financial assets 504.00
Total non-current financial assets 1,97,065.00
Deferred tax assets (net) 28,039.00
Other non-current assets
1 Non Current Tax Asset(net) 3,067.00
2 others 501.00
Total of other non-current assets 3,568.00
Total non-current assets 4,57,944.00
2 Current assets
Inventories 11,947.00
Current financial asset
Current investments 0.00
Trade receivables, current 68,280.00
Cash and cash equivalents 319.00
Bank balance other than cash and cash equivalents 270.00
Loans, current 24,967.00
Other current financial assets
Total of other current financial assets 4,050.00
Total current financial assets 97,886.00
Current tax assets (net)
Other current assets
1 Other current assets 6,951.00
Total of other current assets 6,951.00
Total current assets 1,16,784.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 5,74,728.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,387.00
Other equity 3,27,455.00
Total equity attributable to owners of parent 3,28,842.00
Non controlling interest
Total equity 3,28,842.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 18,660.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 1,701.00
Total of other non-current financial liabilities 1,701.00
Total non-current financial liabilities 20,361.00
Provisions, non-current 4,693.00
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
1 Other non-current liabilities 37.00
Total of other non-current liabilities 37.00
Total non-current liabilities 25,091.00
Current liabilities
Current financial liabilities
Borrowings, current 1,76,623.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 985.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 29,138.00
Total Trade payable 30,123.00
Other current financial liabilities
1 Other current financial liabilities 7,590.00
2 Lease Liabilities 653.00
Total of other current financial liabilities 8,243.00
Total current financial liabilities 2,14,989.00
Other current liabilities 1,905.00
1 Other current liabilities 1,905.00
Total of other current liabilities 1,905.00
Provisions, current 3,097.00
Current tax liabilities (Net) 804.00
Deferred government grants, Current 0.00
Total current liabilities 2,20,795.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 2,45,886.00
Total equity and liabilites 5,74,728.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Employee Benefit 17.00 33.00
Total Amount of items that will not be reclassified to profit and loss 17.00 33.00
2 Income tax relating to items that will not be reclassified to profit or loss 4.00 8.00
3 Amount of items that will be reclassified to profit and loss
1 Cash Flow hedge (94.00) (94.00)
Total Amount of items that will be reclassified to profit and loss (94.00) (94.00)
4 Income tax relating to items that will be reclassified to profit or loss (24.00) (24.00)
5 Total Other comprehensive income (57.00) (45.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 14,766.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 8,422.00
Adjustments for decrease (increase) in inventories 189.00
Adjustments for decrease (increase) in trade receivables, current (37,564.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (125.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (276.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 8,186.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (668.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 8,086.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 350.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (31.00)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 3,572.00
Adjustments for share-based payments 440.00
Adjustments for fair value losses (gains) (47.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (21.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (16,631.00)
Net cash flows from (used in) operations (1,865.00)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,668.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (3,533.00)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 3,900.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 1,996.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 47.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 55.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 15,551.00
Net cash flows from (used in) investing activities 9,757.00
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 26,129.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 1,136.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 10,850.00
Repayments of borrowings 23,642.00
Payments of lease liabilities 386.00
Dividends paid 9,988.00
Interest paid 13,041.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 519.00
Net cash flows from (used in) financing activities (8,423.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (2,199.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (2,199.00)
Cash and cash equivalents cash flow statement at beginning of period 2,518.00
Cash and cash equivalents cash flow statement at end of period 319.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Walker Chandiok & Co LLP Yes 31-05-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Eris Oaknet Healthcare Private Limited Eris Therapeutics Limited Holding Company Any other transaction Royalty income 0.00 NA 39.00 0.00 0.00
2 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Royalty income 0.00 NA 16.00 0.00 0.00
3 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Royalty income 0.00 NA 41.00 0.00 0.00
4 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Royalty income 0.00 NA 1.00 0.00 0.00
5 Aprica Healthcare Limited Eris Lifesciences Limited Step Down Wholly Owned Subsidiary Any other transaction Royalty income 0.00 NA 1.00 0.00 0.00
6 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Royalty income 0.00 NA 901.00 0.00 0.00
7 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Royalty income 0.00 NA 16.00 0.00 0.00
8 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Royalty income 0.00 NA 1.00 0.00 0.00
9 Aprica Healthcare Limited Eris Therapeutics Limited Holding Company Any other transaction Royalty income 0.00 NA 3.00 0.00 0.00
10 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 97.00 0.00 0.00
11 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 22.00 0.00 0.00
12 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 114.00 0.00 0.00
13 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 43.00 0.00 0.00
14 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Cross charge operating income 0.00 NA 56.00 0.00 0.00
15 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 7.00 0.00 0.00
16 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Cross charge operating income 31,294.00 Approved on 25-10-2024 7.00 0.00 0.00
17 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 7.00 0.00 0.00
18 Eris Lifesciences Limited Swiss Parenterals Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 39.00 0.00 0.00
19 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 1.00 0.00 0.00
20 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Cross charge operating income 31,294.00 Approved on 25-10-2024 1.00 0.00 0.00
21 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 1.00 0.00 0.00
22 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 57.00 0.00 0.00
23 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 52.00 0.00 0.00
24 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Interest received 0.00 NA 57.00 0.00 0.00
25 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Interest received 0.00 NA 1.00 0.00 0.00
26 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Interest received 31,294.00 Approved on 25-10-2024 9.00 0.00 0.00
27 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Interest received 0.00 NA 851.00 0.00 0.00
28 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 1.00 0.00 0.00
29 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 100.00 0.00 0.00
30 Eris Therapeutics Limited Eris Healthcare Private Limited Wholly owned Subsidiary Interest received 0.00 NA 196.00 0.00 0.00
31 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Interest received 0.00 NA 212.00 0.00 0.00
32 Aprica Healthcare Limited Eris M.J. Biopharm Private Limited Group Company Interest received 31,294.00 Approved on 25-10-2024 19.00 0.00 0.00
33 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 54.00 0.00 0.00
34 Aprica Healthcare Limited Eris Healthcare Private Limited Group Company Interest received 0.00 NA 37.00 0.00 0.00
35 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 46.00 0.00 0.00
36 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Interest received 0.00 NA 977.00 0.00 0.00
37 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 164.00 0.00 0.00
38 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Sale of goods or services 0.00 NA 82.00 0.00 0.00
39 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Sale of goods or services 0.00 NA 42,800.00 0.00 0.00
40 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Sale of goods or services 0.00 NA 43,182.00 0.00 0.00
41 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA 24,017.00 0.00 0.00
42 Eris Therapeutics Limited Aprica Healthcare Limited Wholly owned Subsidiary Sale of goods or services 0.00 NA 197.00 0.00 0.00
43 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA 24,618.00 0.00 0.00
44 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Sale of goods or services 0.00 NA 1.00 0.00 0.00
45 Eris M.J. Biopharm Private Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA 2,109.00 0.00 0.00
46 Eris M.J. Biopharm Private Limited Eris Lifesciences Limited Holding Company Sale of goods or services 0.00 NA 113.00 0.00 0.00
47 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Sale of goods or services 0.00 NA 603.00 0.00 0.00
48 Eris Healthcare Private Limited Eris Therapeutics Limited Group Company Sale of goods or services 0.00 NA 0.00 0.00 0.00
49 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Sale of goods or services 0.00 NA 470.00 0.00 0.00
50 Swiss Parenterals Limited Aprica Healthcare Limited Group Company Sale of goods or services 0.00 NA 33.00 0.00 0.00
51 Eris Bionxt Private Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA 2,067.00 0.00 0.00
52 Eris Bionxt Private Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA 158.00 0.00 0.00
53 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Royalty income 0.00 NA 938.00 0.00 0.00
54 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Any other transaction Royalty income 0.00 NA 2.00 0.00 0.00
55 Eris Oaknet Healthcare Private Limited Eris Therapeutics Limited Holding Company Any other transaction Royalty income 0.00 NA 41.00 0.00 0.00
56 Aprica Healthcare Limited Eris Therapeutics Limited Holding Company Any other transaction Royalty income 0.00 NA 4.00 0.00 0.00
57 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 97.00 0.00 0.00
58 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 21.00 0.00 0.00
59 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 115.00 0.00 0.00
60 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 44.00 0.00 0.00
61 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Cross charge operating income 0.00 NA 56.00 0.00 0.00
62 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 7.00 0.00 0.00
63 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Cross charge operating income 31,294.00 Approved on 25-10-2024 7.00 0.00 0.00
64 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 7.00 0.00 0.00
65 Eris Lifesciences Limited Swiss Parenterals Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 38.00 0.00 0.00
66 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 1.00 0.00 0.00
67 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Cross charge operating income 31,294.00 Approved on 25-10-2024 1.00 0.00 0.00
68 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 1.00 0.00 0.00
69 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 83.00 0.00 0.00
70 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Interest received 0.00 NA 0.00 0.00 0.00
71 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Interest received 0.00 NA 333.00 0.00 0.00
72 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 0.00 0.00 0.00
73 Aprica Healthcare Limited Eris M.J. Biopharm Private Limited Group Company Interest received 31,294.00 Approved on 25-10-2024 34.00 0.00 0.00
74 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 54.00 0.00 0.00
75 Aprica Healthcare Limited Eris Healthcare Private Limited Group Company Interest received 0.00 NA 37.00 0.00 0.00
76 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 158.00 0.00 0.00
77 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 133.00 0.00 0.00
78 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Sale of goods or services 0.00 NA 93.00 0.00 0.00
79 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Sale of goods or services 0.00 NA (3,409.00) 0.00 0.00
80 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Sale of goods or services 0.00 NA 522.00 0.00 0.00
81 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA (520.00) 0.00 0.00
82 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA (30.00) 0.00 0.00
83 Eris Therapeutics Limited Aprica Healthcare Limited Wholly owned Subsidiary Sale of goods or services 0.00 NA 154.00 0.00 0.00
84 Eris M.J. Biopharm Private Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA (130.00) 0.00 0.00
85 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Royalty income 0.00 NA 15.00 0.00 0.00
86 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Royalty income 0.00 NA 71.00 0.00 0.00
87 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Royalty income 0.00 NA 1.00 0.00 0.00
88 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Cross charge operating income 0.00 NA 39.00 0.00 0.00
89 Eris Therapeutics Limited Eris Bionxt private Limited Group Company Any other transaction Cross charge operating income 0.00 NA 73.00 0.00 0.00
90 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Interest received 31,294.00 Approved on 25-10-2024 19.00 0.00 0.00
91 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Interest received 0.00 NA 103.00 0.00 0.00
92 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Interest received 0.00 NA 0.00 0.00 0.00
93 Eris Healthcare Private Limited Eris Therapeutics Limited Group Company Interest received 0.00 NA 94.00 0.00 0.00
94 Eris Bionxt Private Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA (50.00) 0.00 0.00
95 Eris M.J. Biopharm Private Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA 3,350.00 0.00 0.00
96 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Any other transaction Cross charge operating income 0.00 NA 34.00 0.00 0.00
97 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Interest received 0.00 NA 1,050.00 0.00 0.00
98 Eris Lifesciences Limited Swiss Parenterals Limited Wholly owned Subsidiary Sale of goods or services 0.00 NA 58.00 0.00 0.00
99 Eris Therapeutics Limited Swiss Parenterals Limited Group Company Sale of goods or services 0.00 NA 24.00 0.00 0.00
100 Eris M.J. Biopharm Private Limited Eris Healthcare Private Limited Group Company Sale of goods or services 0.00 NA (10.00) 0.00 0.00
101 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Any other transaction Loan closing balance 0.00 NA 0.00 0.00 2,719.00
102 Aprica Healthcare Limited Eris M.J. Biopharm Private Limited Group Company Any other transaction Loan closing balance 31,294.00 Approved on 25-10-2024 0.00 0.00 1,899.00
103 Aprica Healthcare Limited Eris Healthcare Private Limited Group Company Any other transaction Loan closing balance 0.00 NA 0.00 0.00 1,870.00
104 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Loan closing balance 0.00 NA 0.00 0.00 4,376.00
105 Eris Healthcare Private Limited Eris Pharmaceuticals Limited Group Company Any other transaction Loan closing balance 0.00 NA 0.00 0.00 1.00
106 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Loan closing balance 31,294.00 Approved on 25-10-2024 0.00 0.00 1,170.00
107 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Loan closing balance 0.00 NA 0.00 0.00 23,698.00
108 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 276.00
109 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Loan closing balance 0.00 NA 0.00 0.00 5,183.00
110 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Any other transaction Loan closing balance 0.00 NA 0.00 0.00 4,768.00
111 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Loan closing balance 0.00 NA 0.00 0.00 55,043.00
112 Eris Healthcare Private Limited Eris Therapeutics Limited Group Company Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 94.00
113 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 203.00
114 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 197.00
115 Aprica Healthcare Limited Eris M.J. Biopharm Private Limited Group Company Any other transaction Accrued interest receivable 31,294.00 Approved on 25-10-2024 0.00 0.00 53.00
116 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 109.00
117 Aprica Healthcare Limited Eris Healthcare Private Limited Group Company Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 75.00
118 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 204.00
119 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 297.00
120 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Collection not due royalty 0.00 NA 0.00 0.00 32.00
121 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Any other transaction Collection not due royalty 0.00 NA 0.00 0.00 4.00
122 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Collection not due royalty 0.00 NA 0.00 0.00 17.00
123 Aprica Healthcare Limited Eris Therapeutics Limited Holding Company Any other transaction Collection not due royalty 0.00 NA 0.00 0.00 7.00
124 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Collection not due CROSS CHARGE INCOME 0.00 NA 0.00 0.00 557.00
125 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Collection not due CROSS CHARGE INCOME 0.00 NA 0.00 0.00 92.00
126 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Collection not due CROSS CHARGE INCOME 0.00 NA 0.00 0.00 19.00
127 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Collection not due CROSS CHARGE INCOME 31,294.00 Approved on 25-10-2024 0.00 0.00 19.00
128 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Collection not due CROSS CHARGE INCOME 0.00 NA 0.00 0.00 159.00
129 Eris Lifesciences Limited Swiss Parenterals Limited Wholly owned Subsidiary Any other transaction Collection not due CROSS CHARGE INCOME 0.00 NA 0.00 0.00 77.00
130 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 21.00
131 Aprica Healthcare Limited Eris Therapeutics Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 14.00
132 Eris Healthcare Private Limited Aprica Healthcare Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 1.00
133 Eris Bionxt Private Limited Eris Healthcare Private Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 2,336.00
134 Eris Bionxt Private Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 0.00
135 Eris Bionxt Private Limited Eris Healthcare Private Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 (50.00)
136 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 7,610.00
137 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Advance 31,294.00 Approved on 25-10-2024 0.00 0.00 237.00
138 Eris Lifesciences Limited Eris Oaknet Healthcare Private Limited Step Down Wholly Owned Subsidiary Advance 0.00 NA 0.00 0.00 2.00
139 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 359.00
140 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 269.00
141 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 (35,800.00)
142 Eris Lifesciences Limited Eris Oaknet Healthcare Private Limited Step Down Wholly Owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 9.00
143 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 6,090.00
144 Eris Therapeutics Limited Aprica Healthcare Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 374.00
145 Eris Therapeutics Limited Swiss Parenterals Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 21.00
146 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 (6,026.00)
147 Eris M.J. Biopharm Private Limited Eris Healthcare Private Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 (2,009.00)
148 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 490.00
149 Eris Oaknet Healthcare Private Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 286.00
150 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Advance 0.00 NA 0.00 0.00 4.00
151 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 213.00
152 Eris Lifesciences Limited Swiss Parenterals Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 221.00
153 Eris Healthcare Private Limited Eris Therapeutics Limited Group Company Any other transaction Loan closing balance 0.00 NA 0.00 0.00 3,620.00
154 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 0.00
155 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 2,030.00
156 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Accrued interest receivable 31,294.00 Approved on 25-10-2024 0.00 0.00 28.00
157 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Accrued interest receivable 0.00 NA 0.00 0.00 57.00
158 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Collection not due royalty 0.00 NA 0.00 0.00 1,830.00
159 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 1,260.00
160 Eris M.J. Biopharm Private Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 0.00 835.00
161 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 85,910.00
162 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Trade receivable 31,294.00 Approved on 25-10-2024 0.00 0.00 44.00
163 Eris Therapeutics Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 34,139.00
164 Eris Healthcare Private Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 0.00 171.00
165 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Interest received 0.00 NA 0.00 0.00 1,390.00
166 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Collection not due royalty 0.00 NA 0.00 0.00 3.00
167 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Any other transaction Collection not due CROSS CHARGE INCOME 0.00 NA 0.00 0.00 34.00
168 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Collection not due CROSS CHARGE INCOME 0.00 NA 0.00 0.00 112.00
169 Eris Therapeutics Limited Eris Bionxt private Limited Group Company Any other transaction Collection not due CROSS CHARGE INCOME 0.00 NA 0.00 0.00 73.00
170 Aprica Healthcare Limited Eris Therapeutics Limited Holding Company Advance 0.00 NA 0.00 0.00 0.00
171 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Advance 0.00 NA 0.00 0.00 1.00
172 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Loan repaid 0.00 NA 4,600.00 0.00 0.00
173 Eris Lifesciences Limited Eris Oaknet Healthcare Private Limited Step Down Wholly Owned Subsidiary Any other transaction Loan repaid 0.00 NA 187.00 0.00 0.00
174 Eris Lifesciences Limited Swiss Parenterals Limited Wholly owned Subsidiary Any other transaction Loan repaid 0.00 NA 4,400.00 0.00 0.00
175 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Any other transaction Loan repaid 0.00 NA 6,300.00 0.00 0.00
176 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Loan repaid 0.00 NA 40,971.00 0.00 0.00
177 Eris Therapeutics Limited Eris M.J. Biopharm Private Limited Group Company Any other transaction Loan repaid 31,294.00 Approved on 25-10-2024 200.00 0.00 0.00
178 Eris M.J. Biopharm Private Limited Eris Lifesciences Limited Holding Company Any other transaction Loan repaid 0.00 NA 200.00 0.00 0.00
179 Eris Bionxt Private Limited Eris Lifesciences Limited Holding Company Any other transaction Loan repaid 0.00 NA 6,250.00 0.00 0.00
180 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Loan repaid 0.00 NA 3,089.00 0.00 0.00
181 Eris Healthcare Private Limited Eris Therapeutics Limited Group Company Any other transaction Loan repaid 0.00 NA 10,200.00 0.00 0.00
182 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Loan taken 0.00 NA 8,976.00 0.00 0.00
183 Eris Lifesciences Limited Eris Oaknet Healthcare Private Limited Step Down Wholly Owned Subsidiary Any other transaction Loan taken 0.00 NA 530.00 0.00 0.00
184 Eris Lifesciences Limited Swiss Parenterals Limited Wholly owned Subsidiary Any other transaction Loan taken 0.00 NA 200.00 0.00 0.00
185 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Any other transaction Loan taken 0.00 NA 9,975.00 0.00 0.00
186 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Loan taken 0.00 NA 18,035.00 0.00 0.00
187 Eris M.J. Biopharm Private Limited Aprica Healthcare Limited Group Company Any other transaction Loan taken 0.00 NA 1,150.00 0.00 0.00
188 Eris M.J. Biopharm Private Limited Eris Lifesciences Limited Holding Company Any other transaction Loan taken 0.00 NA 1,175.00 0.00 0.00
189 Eris Bionxt Private Limited Eris Lifesciences Limited Holding Company Any other transaction Loan taken 0.00 NA 15,754.00 0.00 0.00
190 Eris Lifesciences Limited Amit Bakshi Promoter and Managing Director Remuneration 500.00 Approved on 30-06-2025 242.00 0.00 24.00
191 Eris Lifesciences Limited Inderjeet Singh Negi Promoter and Director Remuneration 175.00 Approved on 30-06-2025 61.00 0.00 6.00
192 Eris Lifesciences Limited Kaushal Shah Promoter and Director Remuneration 130.00 Approved on 30-06-2025 83.00 0.00 9.00
193 Eris Lifesciences Limited Krishnakumar Vaidyanathan Director Remuneration 0.00 NA 230.00 0.00 23.00
194 Eris Lifesciences Limited Rajendra Patel Promoter Remuneration 0.00 NA 27.00 0.00 3.00
195 Eris Lifesciences Limited Amit Bakshi Promoter and Managing Director Any other transaction Reimbursement 0.00 NA 1.00 0.00 0.00
196 Eris Lifesciences Limited Inderjeet Singh Negi Promoter and Director Any other transaction Reimbursement 0.00 NA 1.00 0.00 0.00
197 Eris Lifesciences Limited Kaushal Shah Promoter and Director Any other transaction Reimbursement 0.00 NA 1.00 0.00 0.00
198 Eris Lifesciences Limited Krishnakumar Vaidyanathan Director Any other transaction Reimbursement 0.00 NA 1.00 0.00 0.00
199 Eris Lifesciences Limited Rajendra Patel Promoter Any other transaction Reimbursement 0.00 NA 1.00 0.00 0.00
200 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Other current financial assets 0.00 NA 0.00 26,130.00 0.00
201 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Any other transaction Loan closing balance 0.00 NA 0.00 2,721.00 0.00
202 Aprica Healthcare Limited Eris M.J. Biopharm Private Limited Group Company Any other transaction Loan closing balance 31,294.00 Approved on 25-10-2024 0.00 749.00 0.00
203 Aprica Healthcare Limited Eris Healthcare Private Limited Group Company Any other transaction Loan closing balance 0.00 NA 0.00 1,871.00 0.00
204 Eris Healthcare Private Limited Eris Pharmaceuticals Limited Group Company Any other transaction Loan closing balance 0.00 NA 0.00 2.00 0.00
205 Eris Lifesciences Limited Aprica Healthcare Limited Step Down Wholly Owned Subsidiary Any other transaction Loan closing balance 0.00 NA 0.00 1.00 0.00
206 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Loan closing balance 0.00 NA 0.00 3,089.00 0.00
207 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Loan closing balance 31,294.00 Approved on 25-10-2024 0.00 205.00 0.00
208 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Loan closing balance 0.00 NA 0.00 46,637.00 0.00
209 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Loan closing balance 0.00 NA 0.00 3.00 0.00
210 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Loan closing balance 0.00 NA 0.00 4,840.00 0.00
211 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Any other transaction Loan closing balance 0.00 NA 0.00 8,969.00 0.00
212 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Any other transaction Loan closing balance 0.00 NA 0.00 10,246.00 0.00
213 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Loan closing balance 0.00 NA 0.00 45,539.00 0.00
214 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Collection not due 0.00 NA 0.00 (20.00) 0.00
215 Aprica Healthcare Limited Eris Healthcare Private Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 1.00 0.00
216 Aprica Healthcare Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 22.00 0.00
217 Aprica Healthcare Limited Eris Therapeutics Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 14.00 0.00
218 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Advance 0.00 NA 0.00 1.00 0.00
219 Eris Healthcare Private Limited Eris Therapeutics Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 128.00 0.00
220 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 7.00 0.00
221 Eris M.J. Biopharm Private Limited Eris Healthcare Private Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 123.00 0.00
222 Aprica Healthcare Limited Eris Therapeutics Limited Holding Company Advance 0.00 NA 0.00 1.00 0.00
223 Eris Lifesciences Limited Eris Oaknet Healthcare Private Limited Step Down Wholly Owned Subsidiary Advance 0.00 NA 0.00 2.00 0.00
224 Swiss Parenterals Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 528.00 0.00
225 Eris Lifesciences Limited Aprica Healthcare Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 78.00 0.00
226 Eris Lifesciences Limited Eris Healthcare Private Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 13,023.00 0.00
227 Eris Lifesciences Limited Eris M.J. Biopharm Private Limited Subsidiary Any other transaction Trade receivable 31,294.00 Approved on 25-10-2024 0.00 41.00 0.00
228 Eris Lifesciences Limited Eris Oaknet Healthcare Private Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 16.00 0.00
229 Eris Lifesciences Limited Eris Therapeutics Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 6,076.00 0.00
230 Eris Therapeutics Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 291.00 0.00
231 Eris Therapeutics Limited Aprica Healthcare Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 5.00 0.00
232 Eris Therapeutics Limited Swiss Parenterals Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 158.00 0.00
233 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Any other transaction Trade receivable 0.00 NA 0.00 47,795.00 0.00
234 Eris M.J. Biopharm Private Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 (350.00) 0.00
235 Eris Oaknet Healthcare Private Limited Eris Lifesciences Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 490.00 0.00
236 Eris Healthcare Private Limited Eris M.J. Biopharm Private Limited Group Company Any other transaction Trade receivable 31,294.00 Approved on 25-10-2024 0.00 7.00 0.00
237 Eris Oaknet Healthcare Private Limited Eris Therapeutics Limited Holding Company Any other transaction Trade receivable 0.00 NA 0.00 287.00 0.00
238 Eris Therapeutics Limited Eris Healthcare Private Limited Group Company Advance 0.00 NA 0.00 2.00 0.00
239 Eris M.J. Biopharm Private Limited Eris Therapeutics Limited Group Company Advance 0.00 NA 0.00 200.00 0.00
240 Eris Healthcare Private Limited Eris Lifesciences Limited Holding Company Advance 0.00 NA 0.00 1.00 0.00
241 Eris Bionxt Private Limited Eris Lifesciences Limited Holding Company Advance 0.00 NA 0.00 2.00 0.00
242 Eris Lifesciences Limited Eris Bionxt private Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 8.00 0.00
243 Eris Lifesciences Limited Swiss Parenterals Limited Wholly owned Subsidiary Any other transaction Trade receivable 0.00 NA 0.00 218.00 0.00
244 Eris Lifesciences Limited Amit Bakshi Promoter and Managing Director Remuneration 500.00 Approved on 30-06-2025 0.00 25.00 0.00
245 Eris Lifesciences Limited Kaushal Shah Promoter and Director Remuneration 175.00 Approved on 30-06-2025 0.00 10.00 0.00
246 Eris Lifesciences Limited Inderjeet Singh Negi Promoter and Director Remuneration 130.00 Approved on 30-06-2025 0.00 7.00 0.00
247 Eris Lifesciences Limited Rajendra Patel Promoter Remuneration 0.00 NA 0.00 4.00 0.00
248 Eris Lifesciences Limited Krishnakumar Vaidyanathan Director Remuneration 0.00 NA 0.00 24.00 0.00
249 Eris Lifesciences Limited Parv Amit Bakshi Promoter Group Remuneration 0.00 Approved under omnibus approval 0.00 3.00 0.00
250 Eris Lifesciences Limited Sarthak Negi Promoter Group Remuneration 0.00 Approved under omnibus approval 0.00 1.00 0.00
251 Eris Bionxt Private Limited Levim Lifetech Private Limited Associate Company Any other transaction Loan Given 31,294.00 Approved on 25-10-2024 0.00 4,700.00 0.00
252 Eris M.J. Biopharm Private Limited M.J. Biopharm Private Limited Entity related to Director of Subsidiary Purchase of goods or services 31,294.00 Approved on 25-10-2024 0.00 462.00 0.00
253 Swiss Parenterals Limited Deutsche Labs Entity related to Director of Subsidiary Purchase of goods or services 0.00 NA 0.00 67.00 0.00
254 Swiss Parenterals Limited HealthBest Pvt. Ltd. Entity related to Director of Subsidiary Any other transaction Rent 0.00 NA 0.00 1.00 0.00
255 Eris Lifesciences Limited Parv Amit Bakshi Promoter Group Remuneration 0.00 Approved under omnibus approval 23.00 0.00 3.00
256 Eris Lifesciences Limited Sarthak Negi Promoter Group Any other transaction Reimbursement 0.00 Approved under omnibus approval 3.00 0.00 0.00
257 Eris Lifesciences Limited Parv Amit Bakshi Promoter Group Any other transaction Reimbursement 0.00 Approved under omnibus approval 1.00 0.00 0.00
258 Eris Bionxt Private Limited Levim Lifetech Private Limited Associate Company Loan 31,294.00 Approved on 25-10-2024 2,300.00 0.00 2,280.00
259 Eris Lifesciences Limited M.J. Biopharm Private Limited Entity related to Director of Subsidiary Purchase of goods or services 31,294.00 Approved on 25-10-2024 63.00 0.00 0.00
260 Eris M.J. Biopharm Private Limited M.J. Biopharm Private Limited Entity related to Director Purchase of goods or services 31,294.00 Approved on 25-10-2024 1,897.00 0.00 977.00
261 Swiss Parenterals Limited SWISS PHARMA PVT LTD Entity related to Mr. Naishadh Shah Purchase of goods or services 0.00 NA 1.00 0.00 0.00
262 Swiss Parenterals Limited Deutsche Labs Entity related to Mr. Naishadh Shah Purchase of goods or services 0.00 NA 465.00 0.00 212.00
263 Swiss Parenterals Limited Deutsche Labs Entity related to Mr. Naishadh Shah Sale of goods or services 0.00 NA 0.00 0.00 0.00
264 Swiss Parenterals Limited HealthBest Pvt. Ltd. Entity related to Mr. Naishadh Shah Any other transaction Rent 0.00 NA 9.00 0.00 2.00
265 Swiss Parenterals Limited PIYUSH THAKKAR KMP of Subsidiary Remuneration 0.00 NA 18.00 0.00 0.00
266 Swiss Parenterals Limited NAISHADH V SHAH Director of Subsidiary Remuneration 0.00 NA 199.00 0.00 0.00
Total value of transaction during the reporting period 2,45,655.00